Postpartum Venous Thromboembolism: Altitudinal Gradients, Decadal Trends, and PE‐Specific Risk Profiling in Highland Populations
Canadian Respiratory Journal · 2026-01 · 2026 (1)
DOI: 10.1155/carj/3703610 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Respiratory Journal, online erschienen am 28.06.2026. Verfasst von Jianbo Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Emergency Department, People's Hospital of Xizang Autonomous Region, Lhasa, China. Hauptthemen laut MEDLINE: Altitude, Venous Thromboembolism, Pulmonary Embolism, Puerperal Disorders. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xizang Natural Science Foundation, Group Medical Aid to Xizang Medical Proiect Funding.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
This study primarily analyzed differences in venous thromboembolism (VTE) characteristics across altitudes and their temporal trends during the puerperium. Additionally, it identified independent risk factors for postpartum pulmonary embolism (PE).
Methods
This retrospective study reviewed all postpartum VTE cases at People’s Hospital of Xizang Autonomous Region between 2015 and 2024.
Results
This cohort study of 172 postpartum women (median age 31 [IQR 26–36]) compared high‐altitude (HA, n = 109) and very high‐altitude (VHA, n = 63) groups. PE proportion was significantly higher in VHA vs. HA ( p = 0.033). VHA subjects also showed significant elevated preterm delivery ( p = 0.033) and ≥ 3 deliveries ( p < 0.001). Joinpoint regression (2015–2024) revealed biphasic trends: significant early‐phase escalations in VTE (APC = 18.05%) and deep vein thrombosis (DVT) (APC = 19.66%) during 2015–2022 ( p < 0.05), followed by clinically relevant (though statistically nonsignificant) late‐phase reductions. PE proportion demonstrated a significant overall increase (APC = 18.77%, p < 0.05). In multivariate analysis, four independent predictors significantly increased PE risk: altitude gradient (OR 1.035, p < 0.001), multiparity (OR 2.548, p = 0.004), hypertension or eclampsia (OR 1.797, p = 0.001), and structural heart disease (OR 1.988, p < 0.001).
Conclusion
This decade‐long analysis (2015–2024) revealed significant altitudinal gradients in postpartum VTE. Clinically significant escalation of postpartum VTE burden in high‐altitude populations warrants urgent intervention. Integrated multiparity management and enhanced comorbidity control are critical future initiatives for resolving key perinatal thrombotic risk bottlenecks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Emergency Department, People's Hospital of Xizang Autonomous Region, Lhasa, China.
- Emergency Department, Peking University People's Hospital, Beijing, China, pku.edu.cn.
ORCID-Profile: Zhenzhong Yang, Lobsang Cering, Guiying Dong
Förderung
- Xizang Natural Science Foundation, Group Medical Aid to Xizang Medical Proiect Funding
Zitieren
APA
Yu, J., Chodron, L., Chodron, T., Cering, J., Gao, P., Zheng, X., Shi, F. E., Yang, Z., Cering, L., & Dong, G. (2026). Postpartum Venous Thromboembolism: Altitudinal Gradients, Decadal Trends, and PE‐Specific Risk Profiling in Highland Populations. Canadian Respiratory Journal, 2026(1). https://doi.org/10.1155/carj/3703610
Vancouver
Yu J, Chodron L, Chodron T, Cering J, Gao P, Zheng X, et al. Postpartum Venous Thromboembolism: Altitudinal Gradients, Decadal Trends, and PE‐Specific Risk Profiling in Highland Populations. Canadian Respiratory Journal. 2026;2026(1). doi:10.1155/carj/3703610
BibTeX
@article{Yu2026,
author = {Yu, Jianbo and Chodron, Lobsang and Chodron, Tenzin and Cering, Jo'nga and Gao, Peiliang and Zheng, Xiaoxiao and Shi, Fang-E and Yang, Zhenzhong and Cering, Lobsang and Dong, Guiying},
title = {Postpartum Venous Thromboembolism: Altitudinal Gradients, Decadal Trends, and PE‐Specific Risk Profiling in Highland Populations},
journal = {Canadian Respiratory Journal},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/carj/3703610}
}
EUVIMED